{"organizations": [], "uuid": "5ddad34d4f8c92ed5e391cf66e5601f1906d6d6c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alder-biopharmaceuticals-inc-to-pr/brief-alder-biopharmaceuticals-inc-to-present-new-phase-3-migraine-prevention-data-for-eptinezumab-idUSFWN1RV0KL", "country": "US", "domain_rank": 408, "title": "BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-18T15:47:00.000+03:00", "replies_count": 0, "uuid": "5ddad34d4f8c92ed5e391cf66e5601f1906d6d6c"}, "author": "", "url": "https://www.reuters.com/article/brief-alder-biopharmaceuticals-inc-to-pr/brief-alder-biopharmaceuticals-inc-to-present-new-phase-3-migraine-prevention-data-for-eptinezumab-idUSFWN1RV0KL", "ord_in_thread": 0, "title": "BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-alder biopharmaceuticals inc", "sentiment": "negative"}, {"name": "migraine prevention data for eptinezumab", "sentiment": "negative"}, {"name": "alder biopharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "evention data for eptinezumab reuters staff", "sentiment": "none"}, {"name": "eptinezumab", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 50 PM / Updated 8 minutes ago BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab Reuters Staff 1 Min Read \nApril 18 (Reuters) - Alder Biopharmaceuticals Inc: \n* ALDER BIOPHARMACEUTICALS INC - TO PRESENT NEW PHASE 3 MIGRAINE PREVENTION DATA FOR EPTINEZUMAB AT 70TH ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-18T15:47:00.000+03:00", "crawled": "2018-04-18T16:04:08.005+03:00", "highlightTitle": ""}